A prospective, controlled, randomized, assessor-blind, comparative study of a new oral bowel cleanser (Sodium Picosulfate/Magnesium Citrate) versus existing oral bowel cleanser (Magnesium Citrate) in pediatric colonoscopy preparation.

A prospective, controlled, randomized, assessor-blind, comparative study of a new oral bowel cleanser (Sodium Picosulfate/Magnesium Citrate) versus existing oral bowel cleanser (Magnesium Citrate) in pediatric colonoscopy preparation. - A prospective, controlled, randomized, assessor-blind, comparative study of a new oral bowel cleanser (Sodium Picosulfate/Magnesium Citrate) versus existing oral bowel cleanser (Magnesium Citrate) in pediatric colonoscopy preparation.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046015

Enrollment

126

Registered

2021-11-15

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease, Functional gastrointestinal disorders, Eosinophilic gastroenteritis, Colorectal polyps, others

Interventions

PICOPREP MAGCOROL Powder

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children 6-18 years old who will undergo colonoscopy in our department

Exclusion criteria

Exclusion criteria: Patients with emergency endoscopy, intestinal occlusion, toxic megacolon, electrolyte abnormalities, previous ductal resection, metabolic disorders, renal disorders, cardiac disorders, post-transplant acute GVHD suspicion, weight under 20 kg, Patients with a history of PICO administration and others(treating physicians judged as inappropriate)

Design outcomes

Primary

Measure	Time frame
Bowel cleansing effect by Boston bowel preparation scale	—

Secondary

Measure	Time frame
Side effects (nausea, vomiting and abdominal pain during administration, electrolytes and renal function on the day of CS) Patient acceptability (taste, ease of taking, dosage, desire for re-administration, overall evaluation) Parental acceptability (overall evaluation)	—

Countries

Japan

Contacts

Public ContactTomoko Hara

Saitama children's Medical Center Division of Gastroenterology and Hepatology

haraping2mail@gmail.com048-601-2200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026